Mega-cap tech and AI stocks carried major indexes in thin holiday trading, while healthcare strength after Novo Nordisk’s Wegovy pill approval added selective support amid a resilient economic backdrop.
As 2025 draws to a close, the "Magnificent Seven" era of market dominance is facing its most significant challenge yet. While the first half of the year was characterized by a relentless surge in mega-cap technology stocks, the final quarter of 2025 has seen a decisive shift in investor sentiment—
As the final week of 2025 unfolds, the U.S. economy appears to have achieved the elusive "soft landing" that economists have debated for years. Despite a tumultuous fourth quarter marked by a historic 43-day government shutdown and the implementation of aggressive new trade policies, the final batch of economic
As the curtain closes on 2025, the technology sector has once again defied the gravity of a cooling global economy. Despite persistent geopolitical tensions, a softening labor market, and a year defined by the "Great Rotation" into defensive sectors, the titans of software and hardware have solidified their position as
As the 2025 calendar year draws to a close, the U.S. equity markets have delivered a pre-holiday gift to investors, with major indices scaling new all-time highs on December 23, 2025. The S&P 500 reached a milestone of 6,916 during the session, while the Nasdaq Composite surged
As the final full trading week of 2025 unfolds, the traditional end-of-year "quiet tape" is proving to be anything but silent. Despite the holiday-shortened schedule and trading volumes plummeting to nearly 50% of their annual averages, a series of high-stakes economic data releases and corporate breakthroughs have injected unexpected volatility
As the final trading days of 2025 approach, the financial world is witnessing a rare and paradoxical phenomenon: a powerful stock market rally occurring simultaneously with a sharp rise in long-term bond yields. While traditional economic theory suggests that higher yields—which increase borrowing costs and discount the value of
As the curtain begins to close on 2025, the financial world finds itself in a state of cognitive dissonance. On the surface, the markets are celebrating a period of unprecedented prosperity; the S&P 500 (NYSEARCA:SPY) is hovering near all-time highs of 6,839, capping off a staggering three-year
As the final trading days of 2025 wind down, the global financial landscape is witnessing a structural shift that many analysts are calling the "Great Rebalancing." For much of the last three years, the market’s fate was tied almost exclusively to a handful of tech titans known as the
CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing for the fiscal year ended September 30, 2025, the company has officially shed its "development-stage" label, entering
Multi Ways Holdings (NYSE American: MWG) has sent a powerful signal to the global markets, reporting a staggering 87.7% year-over-year revenue surge for the first half of 2025. This explosive growth, which saw revenues climb to $26.44 million from $14.09 million in the previous year, marks a
As of December 23, 2025, the global semiconductor landscape remains a volatile chessboard, with Advanced Micro Devices (NASDAQ:AMD) currently positioned at the center of a high-stakes geopolitical maneuver. The company is navigating a complex web of rumors regarding its China-specific MI308 AI accelerator, just as the U.S. government
